Valuation: Egetis Therapeutics AB

Market Cap 3.23B 339M 294M 275M 251M 472M 32.38B 480M 1.26B 16.17B 1.27B 1.25B 54.45B P/E 2026 *
476x
P/E 2027 * -21.2x
Enterprise Value 2.73B 288M 249M 233M 213M 400M 27.44B 407M 1.07B 13.7B 1.08B 1.06B 46.14B EV / Sales 2026 *
6.23x
EV / Sales 2027 * 8.2x
Free-Float
40.16%
Yield 2026 *
-
Yield 2027 * -
1 day-0.72%
1 week+13.58%
Current month+15.67%
1 month+14.14%
3 months+7.10%
6 months+34.24%
Current year+29.96%
1 week 6.39
Extreme 6.39
7.21
1 month 5.86
Extreme 5.86
7.21
Current year 4.23
Extreme 4.23
7.21
1 year 3.62
Extreme 3.625
7.21
3 years 3.02
Extreme 3.025
9.3
5 years 3
Extreme 3.005
9.3
10 years 3
Extreme 3.005
50.75
Manager TitleAgeSince
Chief Executive Officer 50 2017-06-15
Director of Finance/CFO 47 2017-12-30
Chief Tech/Sci/R&D Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 65 2016-12-31
Director/Board Member 65 2016-12-31
Chairman 61 2024-05-05
Date Insider Type Main position Quantity % Market Cap.
5/13/26 Sell

Chief Executive Officer

-286,071 0.0724%
5/11/26 Fiscal year

Chief Financial Officer

264,880 0.0670%
1/16/26 Buy

Chairman

150,000 0.0380%
Change 5-day change 1-year change 3-year change Capi.($)
-0.72%+13.58%+20.07%+56.66% 343M
-0.70%+24.68%+76.72%+103.05% 70.85B
-2.35%+3.71%+31.77%+63.89% 55.41B
-1.62%+34.66%+21.01%+483.49% 29.43B
-0.30%+18.51%+56.61%+4.86% 24.12B
0.00%+0.60%-16.89%-12.00% 23.31B
+0.05%+7.96%+44.21%-22.57% 18.37B
+9.77%+25.32%+252.40%+442.16% 16.99B
0.00%+10.84%+31.14%+628.97% 16.1B
-3.08%-6.77%+36.08%+142.70% 13.12B
Average +0.10%+352.32%+55.31%+189.12% 26.81B
Weighted average by Cap. -0.40%+348.73%+55.47%+164.24%

Financials

2026 *2027 *
Net sales 439M 46.14M 39.93M 37.38M 34.13M 64.2M 4.4B 65.31M 172M 2.2B 173M 169M 7.4B 353M 37.09M 32.1M 30.05M 27.44M 51.61M 3.54B 52.51M 138M 1.77B 139M 136M 5.95B
Net income 302M 31.79M 27.52M 25.76M 23.52M 44.25M 3.03B 45.01M 118M 1.52B 119M 117M 5.1B -95.62M -10.05M -8.7M -8.15M -7.44M -13.99M -959M -14.23M -37.42M -479M -37.75M -36.93M -1.61B
Net Debt -492M -51.76M -44.8M -41.93M -38.29M -72.02M -4.94B -73.27M -193M -2.47B -194M -190M -8.31B -334M -35.12M -30.4M -28.46M -25.98M -48.88M -3.35B -49.72M -131M -1.67B -132M -129M -5.64B
Logo Egetis Therapeutics AB
Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
Employees
44
Date Price Change Volume
26-08-11 SEK 6.940 -0.72% 340,386
26-08-10 SEK 6.990 -1.27% 1,121,387
26-08-07 SEK 7.080 +3.36% 1,256,588
26-08-06 SEK 6.850 +1.63% 731,610
26-08-05 SEK 6.740 +5.64% 803,369
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
6.940SEK
Average target price
15.33SEK
Spread / Average Target
+120.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EGTX Stock